Moolec Science (MLEC) Stock Price, News & Analysis

Company Overview

Moolec Science (NASDAQ:MLEC) is a clinical-stage biotechnology company specializing in the development of synthetic messenger RNA (mRNA) molecules for therapeutic and cosmetic applications. Leveraging proprietary chemistry and formulation techniques, the company designs tailored mRNA constructs that target skin health, tissue regeneration, and localized delivery without the need for viral vectors. Its technology platform aims to unlock the potential of mRNA beyond vaccines by enabling controlled expression of therapeutic proteins and peptides directly within targeted tissues.

The company’s research portfolio includes mRNA-based products for dermatological conditions such as wound healing, anti-aging, and hair regrowth. Moolec Science has advanced several preclinical programs focused on enhancing skin barrier function and promoting tissue repair. In parallel, the firm is exploring innovative bioelectronic approaches that combine synthetic mRNA with electronic interfaces to modulate cellular activity, reflecting its ambition to create next-generation precision therapies.

Founded as a spin-out from leading academic institutions, Moolec Science maintains research laboratories in Tel Aviv and a presence in North America to facilitate collaboration with global partners. Since its inception, the company has attracted support from biotechnology investors and has engaged in strategic alliances for formulation development and clinical translation. Its cross-continental operations enable access to diverse talent pools and regulatory expertise, positioning it for advancement through clinical milestones.

Moolec Science is led by a team of experienced biotech executives and scientific advisors. The company’s founder and chairman, Professor Dan Peer, brings extensive expertise in RNA therapeutics and nanomedicine, while the executive leadership team combines backgrounds in drug development, regulatory affairs, and commercial strategy. Together, they aim to harness the versatility of synthetic mRNA to address unmet medical needs and establish new standards in cosmeceutical and therapeutic innovation.

Key Stats

• Today's Range: $4.60 to $5.51
• 50-Day Range: $5.03 to $9.30
• 52-Week Range: $4.60 to $10.90
• Volume: 20,163 shs
• Average Volume: 5,099 shs
• Market Capitalization: $20.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Moolec Science Stock Analysis - MarketRank™

Moolec Science scored higher than 19% of companies evaluated by MarketBeat, and ranked 148th out of 153 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Moolec Science.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Moolec Science is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moolec Science is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moolec Science has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of Moolec Science has been sold short.

Short Interest Ratio / Days to Cover

Moolec Science has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moolec Science has recently decreased by 47.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moolec Science does not currently pay a dividend.

Dividend Growth

Moolec Science does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.18% of the float of Moolec Science has been sold short.

Short Interest Ratio / Days to Cover

Moolec Science has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moolec Science has recently decreased by 47.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Moolec Science has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Moolec Science this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Moolec Science to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Moolec Science insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.90% of the stock of Moolec Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.07% of the stock of Moolec Science is held by institutions.

MLEC Stock Analysis - Frequently Asked Questions

How have MLEC shares performed this year?

Moolec Science's stock was trading at $8.00 at the beginning of the year. Since then, MLEC shares have decreased by 37.1% and is now trading at $5.03.

How were Moolec Science's earnings last quarter?

Moolec Science SA (NASDAQ:MLEC) issued its quarterly earnings results on Wednesday, April, 16th. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). The firm had revenue of $2.64 million for the quarter, compared to the consensus estimate of $2.01 million. Moolec Science had a negative trailing twelve-month return on equity of 162.27% and a negative net margin of 105.71%.

When did Moolec Science's stock split?

Moolec Science shares reverse split on Wednesday, May 14th 2025.The 1-10 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Moolec Science?

Shares of MLEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Moolec Science own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Moolec Science investors own include PayPal (PYPL), TriNet Group (TNET), Tesla (TSLA), ABM Industries (ABM), Adverum Biotechnologies (ADVM), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 4/16/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 9/30/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: AGRI OPERATIONS
• Sub-Industry: Trading
• Current Symbol: NASDAQ:MLEC
• CIK: 1937737
• Web: moolecscience.com
• Phone: 650-515-3930
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.31 million
• Net Margins: -105.71%
• Pretax Margin: N/A
• Return on Equity: -162.27%
• Return on Assets: -25.16%

Debt

• Debt-to-Equity Ratio: 6.99
• Current Ratio: 1.48
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $5.62 million
• Price / Sales: 3.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.77 per share
• Price / Book: 2.84

Miscellaneous

• Outstanding Shares: 4,010,000
• Free Float: 3,214,000
• Market Cap: $20.17 million
• Optionable: Not Optionable
• Beta: -0.38